SpringerLink
Log in

BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report

  • Original Article
  • Published:
Pathology & Oncology Research

A Correction to this article was published on 05 March 2019

This article has been updated

Abstract

Breast cancer is currently the leading cause of cancer morbidity and mortality among Algerian women. In this study, we aimed to investigate the mutation spectrum of BRCA1 and BRCA2 genes in hereditary breast/ovarian cancer (HBOC) families from the Aures region (eastern Algeria). High risk breast/ovarian cancer families were selected from overall 1162 consecutive patients collected from cancer registry of anticancer center of Batna. Breast cancers were diagnosed between 2011 and 2015. Recurrent mutations on BRCA1 and BRCA2 previously found in Algerian patients were screened using PCR-direct sequencing in 113 HBOC families. In addition, for the first time in Algeria, HBOC patients were analyzed by NGS using a cancer panel of 30 hereditary cancer genes or BRCA1/2 genetic test. Six distinct deleterious mutations in BRCA1 and BRCA2 and a new VUS in PALB2 were detected in ten patients. Two distinct BRCA2 pathogenic variants c.1813dupA and c.8485C > T detected in two young female triple negative breast cancer (TNBC) patients, respectively, with a family history of male breast cancer, are reported here for the first time in Algerian population. Interestingly, we also detected a BRCA exon 15 deletion in two unrelated young female TNBC patients with strong family history of breast/ovarian cancer. Our study showed differences in the distribution of the mutation spectrum of BRCA genes between the Aures region and the north central region of Algeria. Our results will contribute in the implementation of genetic counseling and testing for patients and families at risk of hereditary breast and ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Change history

  • 05 March 2019

    The original version of this article unfortunately contained an error in the abstract section and Figure 2h image.

Abbreviations

Array–CGH:

Array Comparative Genomic Hybridization

ER:

Estrogen Receptor,

CISH:

Chromogenic In Situ Hybridization,

HER2:

Human Epidermal growth factor Receptor 2,

HBOC:

Hereditary Breast and Ovarian Cancer

Ki67:

Antigen Ki67

IDC:

Invasive Ductal Carcinoma,

IHC:

Immunohistochemistry

ILC:

Invasive Lobular Carcinoma,

LGR:

Large Genomic Rearrangement

MC:

Mixed Carcinoma (invasive ductal and invasive lobular)

MLPA:

Multiplex Ligation Probe Amplification

NGS:

Next Generation Sequencing

PR:

Progesterone Receptor

TNBC:

Triple Negative Breast Cancer

VUS:

Variant of Uncertain Significance

References

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr. Accessed on 12/1/2018

  2. GLOBOCAN (2012) Breast cancer incidence and mortality worldwide, 2012. International agency for research on cancer. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 4 Jan 2018

  3. Perou CM, Sørlie T, Eisen MB, Van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumors. Nature 406:747–752

    Article  CAS  PubMed  Google Scholar 

  4. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100:10393–10398

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel members (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast Cancer 2011. Ann Oncol 22:1736–1747. https://doi.org/10.1093/annonc/mdr304

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Cherbal F, Gaceb H, Mehemmai C, Saiah I, Bakour R, Rouis AO, Boualga K, Benbrahim W, Mahfouf H (2015) Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study. Breast Dis 35(2):95–102. https://doi.org/10.3233/BD-150398

    Article  PubMed  Google Scholar 

  7. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, and the BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H (2017) BRCA1 and BRCA2 cohort consortium. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416. https://doi.org/10.1001/jama.2017.7112

    Article  CAS  PubMed  Google Scholar 

  8. Purnomosari D, Pals G, Wahyono A, Aryandono T, Manuaba TW, Haryono SJ, van Diest PJ (2007) BRCA1 and BRCA2 germline mutation analysis in the Indonesian population. Breast Cancer Res Treat 106(2):297–304

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Villarreal-Garza C, Weitzel JN, Llacuachaqui M, Sifuentes E, Magallanes-Hoyos MC, Gallardo L, Alvarez-Gómez RM, Herzog J, Castillo D, Royer R, Akbari M, Lara-Medina F, Herrera LA, Mohar A, Narod SA (2015) The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer. Breast Cancer Res Treat 150(2):389–394. https://doi.org/10.1007/s10549-015-3312-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yang XR, Devi BCR, Sung H, Guida J, Mucaki EJ, **ao Y, Best A, Garland L, **e Y, Hu N, Rodriguez-Herrera M, Wang C, Jones K, Luo W, Hicks B, Tang TS, Moitra K, Rogan PK, Dean M (2017) Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia. Breast Cancer Res Treat 165(3):687–697. https://doi.org/10.1007/s10549-017-4356-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Palmero EI, Carraro DM, Alemar B et al (2018) The germline mutational landscape of BRCA1 and BRCA2 in Brazil. Sci Rep 8(1):9188. https://doi.org/10.1038/s41598-018-27315-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Zheng Y, Walsh T, Gulsuner S, Casadei S, Lee MK, Ogundiran TO, Ademola A, Falusi AG, Adebamowo CA, Oluwasola AO, Adeoye A, Odetunde A, Babalola CP, Ojengbede OA, Odedina S, Anetor I, Wang S, Huo D, Yoshimatsu TF, Zhang J, Felix GES, King MC, Olopade OI (2018) Inherited breast Cancer in Nigerian women. J Clin Oncol 36(28):2820–2825. https://doi.org/10.1200/JCO.2018.78.3977

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bekada A, Arauna LR, Deba T, Calafell F, Benhamamouch S, Comas D (2015) Genetic heterogeneity in Algerian human populations. PLoS One 10(9):e0138453. https://doi.org/10.1371/journal.pone.0138453

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Cherbal F, Bakour R, Adane S, Boualga K (2012) BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries. Breast Dis 34:1–8

    CAS  PubMed  Google Scholar 

  15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC Cancer staging manual, 7th edn. Springer, New York

    Google Scholar 

  16. Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 6:195–197

    Article  PubMed  PubMed Central  Google Scholar 

  17. Pennacchia I, Carbone A, Di Cerbo A, Vecchio FM, Arena V (2015) 2013 ASCO/CAP updated guidelines for human epidermal growth factor receptor 2 testing: impact on routine practice. Breast 24:285e6

    Article  Google Scholar 

  18. Cherbal F, Bakour R, Adane S, Boualga K, Benais-Pont G, Maillet P (2010) BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families. Dis Markers 28:377–384

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Engert S, Wappenschmidt B, Betz B, Kast K, Kutsche M, Hellebrand H, Goecke TO, Kiechle M, Niederacher D, Schmutzler RK, Meindl A (2008) MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases. Hum Mutat 29:948–958

    Article  CAS  PubMed  Google Scholar 

  20. Tai YC, Domchek S, Parmigiani G, Chen S (2007) Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 99(23):1811–1814

    Article  CAS  PubMed  Google Scholar 

  21. Silvestri V, Barrowdale D, Mulligan AM et al (2016) Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the consortium of investigators of modifiers of BRCA1/2. Breast Cancer Res 18(1):15. https://doi.org/10.1186/s13058-016-0671-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Janavičius R (2010) Founder BRCA1/2mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J 1, 397–412(3)

    Article  PubMed  PubMed Central  Google Scholar 

  23. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17:1082–1089

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, Turnbull C, Houlston R, Shanley S, Butler S, Evans DG, Ross G, Eccles D, Tutt A, Rahman N, TNT Trial TMG., BCSC (UK) (2012) BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer 106:1234–1238

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Meyer P, Landgraf K, Högel B, Eiermann W, Ataseven B (2012) BRCA2 mutations and triple- negative breast cancer. PLoS One 7(5):e38361. https://doi.org/10.1371/journal.pone.0038361

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, Griffin M, Hamilton SA, Frye CA, Silberman MA, Wenstrup RJ, Sandbach JF (2012) Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 118:2787–2782

    Article  CAS  PubMed  Google Scholar 

  27. Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Pelttari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA (2014) Inherited mutations in 17 breast cancer susceptibility genes among a large triple negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 33:304–311. https://doi.org/10.1200/JCO.2014.57.1414

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Wong-Brown MW, Meldrum CJ, Carpenter JE et al (2015) Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat 50:71–80

    Article  Google Scholar 

  29. Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler RK (2017) Germline mutations in triple-negative breast Cancer. Breast Care (Basel) 1:15–19. https://doi.org/10.1159/000455999

    Article  Google Scholar 

  30. Chen H, Wu J, Zhang Z et al (2018) Association between BRCA status and triple-negative breast Cancer: a meta-analysis. Front Pharmacol 9:909. https://doi.org/10.3389/fphar.2018.00909

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Cherbal F, Gaceb H, Mehemmai C, Bakour R, Yatta K, Boukoufa I, Mahfouf H, Boualga K (2016) Abstract 2553 : prevalence of BRCA1 germline mutations in Algerian population: implications for genetic testing and counseling. Cancer Res 76(14 Suppl):2553. https://doi.org/10.1158/1538-7445.AM2016-2553

    Article  Google Scholar 

  32. Troudi W, Uhrhammer N, Sibille C, Dahan C, Mahfoudh W, Bouchlaka Souissi C, Jalabert T, Chouchane L, Bignon YJ, Ben Ayed F, Ben Ammar Elgaaied A (2007) Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia. J Hum Genet 52:915–920

    Article  CAS  PubMed  Google Scholar 

  33. Tazzite A, Jouhadi H, Nadifi S, Aretini P, Falaschi E, Collavoli A, Benider A, Caligo MA (2012) BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants. Gynecol Oncol 125(3):687–692. https://doi.org/10.1016/j.ygyno.2012.03.007

    Article  CAS  PubMed  Google Scholar 

  34. Blay P, Santamaría I, Pitiot AS, Luque M, Alvarado MG, Lastra A, Fernández Y, Paredes Á, Freije JMP, Balbín M (2013) Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (northern Spain). BMC Cancer 13:243. https://doi.org/10.1186/1471-2407-13-243

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Krajc M, Zadnik V, Novaković S, Stegel V, Teugels E, Bešič N, Hočevar M, Vakselj A, de Grève J, Žgajnar J (2014) Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening. Clin Genet 85(1):59–63. https://doi.org/10.1111/cge.12119

    Article  CAS  PubMed  Google Scholar 

  36. Jara L, Morales S, de Mayo T, Gonzalez-Hormazabal P, Carrasco V, Godoy R (2017) Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in central and south American populations. Biol Res 50(1):35. https://doi.org/10.1186/s40659-017-0139-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We deeply thank the patients and their families for their participation. This study was supported by the Algerian National Research Program FNRSDT (D01N01UN160420130007). Farid Cherbal would like to deeply and warmly thank Dr. Alicia Zhou and Color Genomics (Burlingame, California, United States, https://www.color.com) for performing the NGS analysis in our Algerian HBOC patients using Hereditary Cancer Test and Color BRCA1/2 genetic test. Farid Cherbal would like to thank Dr. Philippe Maillet (Ornex, France), Prof. Kada Boualga (Anti Cancer Center, Blida, Algeria), Daoud Cherbal (Paris, France) and Romaissa Cherbal (Paris, France) for their permanent support to the research program on hereditary cancers in Algerian population.

Author information

Authors and Affiliations

  1. Unit of Genetics, Laboratory of Molecular and Cellular Biology, Faculty of Biological Sciences, USTHB, POB 32 El Alia, Bab Ezzouar, 16111, Algiers, Algeria

    Chiraz Mehemmai, Farid Cherbal & Rabah Bakour

  2. Faculty of Sciences of Tunis, University Campus 2092 - El Manar, Tunis, University of Tunis El Manar, Tunis, Tunisia

    Chiraz Mehemmai

  3. Laboratory of Biomedical Genomics and Oncogenetics (LRTI, IPT 05), Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia

    Chiraz Mehemmai, Yosr Hamdi & Sonia Abdelhak

  4. LOBEM, Faculty of Biological Sciences, USTHB, Algiers, Algeria

    Abdelmoumene Guedioura

  5. Anti-cancer center of Batna, Batna, Algeria

    Wassila Benbrahim

Authors
  1. Chiraz Mehemmai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farid Cherbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yosr Hamdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abdelmoumene Guedioura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wassila Benbrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rabah Bakour
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sonia Abdelhak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Farid Cherbal.

Ethics declarations

Conflicts of Interest

The authors declare non conflict of interest.

Ethical Approval

All patients tested for BRCA1 and BRCA2 germline mutations and screened by PCR-direct sequencing and NGS analysis, respectively, signed written informed consent. The study was approved by the institutional review boards and ethical approval was obtained from appropriate institutions (USTHB, CAC Batna, FNRSDT and CNEPRU D01N01UN160420130007, 113 participants, start date: 4/16/2015, end date: 9/28/2016).

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This study has been accepted for a poster presentation (in part) at the 108th annual meeting of American Association for Cancer Research, April 1-5, 2017; Washington, DC. USA

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mehemmai, C., Cherbal, F., Hamdi, Y. et al. BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report. Pathol. Oncol. Res. 26, 715–726 (2020). https://doi.org/10.1007/s12253-019-00586-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-019-00586-4

Keywords

Search

Navigation